BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment

Area of Science:

• Hematology
• Oncology
• Mathematical Biology

Background:

• Imatinib is effective for Philadelphia chromosome-positive chronic myeloid leukemia (CML).
• The impact of imatinib on leukemic stem cell (LSC) burden is not fully understood.
• Reducing LSC burden is crucial for safe imatinib discontinuation.

Purpose of the Study:

• To investigate the dynamics of leukemic stem cells (LSCs) during imatinib therapy.
• To determine if imatinib reduces the LSC burden in CML patients.
• To explore the implications for imatinib treatment discontinuation.

Main Methods:

• Mathematical modeling of BCR-ABL transcript levels.
• Analysis of data from 477 CML patients treated with imatinib.
• Testing of monoexponential, biexponential, and triexponential models for BCR-ABL dynamics.

Main Results:

• Most CML patients exhibit a biexponential decrease in BCR-ABL transcript levels under imatinib.
• A rapid initial decline is followed by a prolonged, gradual decrease.
• This pattern suggests a continuous reduction of LSCs over time.

Conclusions:

• The observed BCR-ABL dynamics are consistent with a gradual reduction of LSCs.
• This sustained LSC reduction may enable safe imatinib discontinuation in some CML patients.
• Mathematical modeling provides insights into CML stem cell dynamics.